HC Wainwright Forecasts Xeris Biopharma Q2 Earnings

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) – Equities research analysts at HC Wainwright issued their Q2 2026 earnings per share estimates for shares of Xeris Biopharma in a report issued on Monday, March 2nd. HC Wainwright analyst B. Folkes expects that the company will post earnings of $0.01 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Xeris Biopharma’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Xeris Biopharma’s Q3 2026 earnings at $0.03 EPS, Q4 2026 earnings at $0.04 EPS, FY2026 earnings at $0.06 EPS, FY2027 earnings at $0.17 EPS, FY2028 earnings at $0.36 EPS, FY2029 earnings at $0.66 EPS and FY2030 earnings at $0.91 EPS.

A number of other research firms have also recently commented on XERS. Oppenheimer reaffirmed an “outperform” rating and set a $18.00 price target on shares of Xeris Biopharma in a research note on Friday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Xeris Biopharma in a research report on Wednesday, January 21st. Piper Sandler upped their target price on Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a research note on Friday, November 7th. Wall Street Zen downgraded Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Barclays assumed coverage on Xeris Biopharma in a report on Monday, December 8th. They set an “overweight” rating and a $9.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Xeris Biopharma has a consensus rating of “Moderate Buy” and a consensus price target of $10.08.

Xeris Biopharma Stock Down 1.3%

XERS stock opened at $5.94 on Wednesday. Xeris Biopharma has a twelve month low of $3.59 and a twelve month high of $10.08. The stock has a market capitalization of $985.56 million, a price-to-earnings ratio of -593.41 and a beta of 0.61. The firm’s fifty day simple moving average is $7.18 and its two-hundred day simple moving average is $7.62.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings results on Monday, March 2nd. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.03. The company had revenue of $85.81 million for the quarter, compared to analyst estimates of $86.00 million. Xeris Biopharma had a negative return on equity of 3.01% and a net margin of 0.19%.

Institutional Investors Weigh In On Xeris Biopharma

Several large investors have recently modified their holdings of XERS. Calamos Advisors LLC purchased a new stake in Xeris Biopharma during the third quarter worth $1,116,000. Voya Investment Management LLC raised its position in shares of Xeris Biopharma by 866.6% in the 3rd quarter. Voya Investment Management LLC now owns 400,079 shares of the company’s stock worth $3,257,000 after acquiring an additional 358,689 shares in the last quarter. Squarepoint Ops LLC raised its position in shares of Xeris Biopharma by 1,679.1% in the 2nd quarter. Squarepoint Ops LLC now owns 284,567 shares of the company’s stock worth $1,329,000 after acquiring an additional 268,572 shares in the last quarter. Savvy Advisors Inc. purchased a new stake in shares of Xeris Biopharma during the 2nd quarter worth $189,000. Finally, Corient Private Wealth LLC bought a new stake in Xeris Biopharma during the second quarter valued at about $320,000. Institutional investors own 42.75% of the company’s stock.

Insider Activity at Xeris Biopharma

In other Xeris Biopharma news, insider Kevin Mcculloch sold 15,000 shares of Xeris Biopharma stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $8.00, for a total transaction of $120,000.00. Following the completion of the sale, the insider directly owned 1,685,426 shares of the company’s stock, valued at $13,483,408. The trade was a 0.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Beth Hecht sold 16,667 shares of the company’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $7.43, for a total value of $123,835.81. Following the completion of the sale, the insider owned 1,308,103 shares of the company’s stock, valued at $9,719,205.29. This represents a 1.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 223,641 shares of company stock worth $1,628,285 over the last three months. Corporate insiders own 4.56% of the company’s stock.

Xeris Biopharma News Summary

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Q4 results: Xeris reported EPS of $0.0615 vs. $0.03 expected and FY2025/quarterly revenue roughly in line at $85.8M, which helped drive an immediate post‑earnings lift. Read More.
• Positive Sentiment: Raised FY‑2026 revenue outlook and growth targets: Management guided revenue of $375–$390M for FY2026 (consensus ~ $370.3M) and is targeting >30% revenue growth next year while investing more behind Recorlev and advancing XP‑8121 — a growth story that underpins the bullish case. Read More.
• Positive Sentiment: Analyst support: HC Wainwright reaffirmed a Buy and set a $10 price target, signaling institutional conviction in Xeris’ growth path. Read More.
• Neutral Sentiment: Full earnings commentary and transcripts are available for investors wanting details on margins, channel dynamics and product-level performance. (Useful for modeling but not a binary catalyst.) Read More.
• Negative Sentiment: Recorlev exclusivity/patent risk: Coverage highlights active patent battles around Recorlev; losing exclusivity or adverse rulings could materially affect future sales and justify investor caution despite current profitability gains. This legal overhang appears to be the main reason traders trimmed positions today. Read More.
• Negative Sentiment: Revenue nuance and reinvestment: Quarterly revenue was just shy of some estimates ($85.8M vs. ~$86M) and management is increasing investment behind Recorlev and pipeline assets — a tradeoff that can pressure near‑term margins and leave execution risk. Read More.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.